Clinical Trials Logo

CIN1 clinical trials

View clinical trials related to CIN1.

Filter by:

NCT ID: NCT06188104 Withdrawn - CIN1 Clinical Trials

Efficacy of Topical 95% TCA in the Treatment of CIN 1 or Less After Low-grade Abnormality of Screening Test

Start date: November 30, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the efficacy of topical 95% TCA in the treatment of CIN 1 or less after low grade abnormality of screening test

NCT ID: NCT05916911 Recruiting - CIN1 Clinical Trials

Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)

Start date: June 7, 2023
Phase: Phase 4
Study type: Interventional

HPV infection can lead to cancer, especially when precancerous lesions have developed and high-risk HPV is present. Glizigen is an oral and intravaginal treatment based on activated glycyrrhizinic acid that has shown potential benefit in patients with HPV. In order to improve the existing evidence, the present study consists of a randomized, double-blind, placebo-compared clinical trial to evaluate the efficacy of combined treatment with Glizigen Oral Solution and Glizigen Vaginal Gel for the resolution of biopsy-confirmed grade 1 cervical intraepithelial neoplasia (CIN-1) in patients with high-risk HPV.

NCT ID: NCT05584332 Terminated - Cervical Cancer Clinical Trials

A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

Start date: December 9, 2022
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 18-45 Years .

NCT ID: NCT05372016 Completed - Cervical Cancer Clinical Trials

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Start date: September 19, 2020
Phase: Phase 3
Study type: Interventional

The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.

NCT ID: NCT05371353 Recruiting - Vaginal Cancer Clinical Trials

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Start date: May 14, 2022
Phase:
Study type: Observational

To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.

NCT ID: NCT05027776 Recruiting - Vaginal Cancer Clinical Trials

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Start date: September 15, 2021
Phase: Phase 3
Study type: Interventional

This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years

NCT ID: NCT04895020 Recruiting - Cervical Cancer Clinical Trials

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Start date: May 28, 2021
Phase: Phase 3
Study type: Interventional

This phase 3 study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese females aged 9 to 45 years

NCT ID: NCT04607850 Completed - HPV Infection Clinical Trials

Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions

Start date: March 16, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1b/2 multi-centre study evaluating the safety, efficacy and immunogenicity of prime-boost vaccines ChAdOx1-HPV and MVA-HPV in women with HPV related low grade cervical lesions.

NCT ID: NCT04425291 Completed - Cervical Cancer Clinical Trials

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Start date: May 28, 2020
Phase: Phase 3
Study type: Interventional

The study will evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccine in Chinese healthy females 20 to 45 years of age.

NCT ID: NCT04422366 Recruiting - Cervical Cancer Clinical Trials

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Start date: April 28, 2020
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years .